Skip to main content
. 2021 Jun 21;13(12):3084. doi: 10.3390/cancers13123084

Figure 7.

Figure 7

Order of events: selicrelumab demonstrated no significant difference between co-stimulation and anti-CD20 treatment. Comparison between CD40 stimulation simultaneously with anti-CD20 mAbs treatment for 48 h, and CD40 stimulation (48 h) before anti-CD20 mAb treatment (24 h), for co-culture system and aCD40XL (n = 6). Bars represent the mean ± SEM: * p <0.05 (unpaired t-test).